Skip to content
Wired News Engine – Lifestyle
Author:
Innovent Biologics,Inc
/C O R R E C T I O N — Innovent Biologics/
May 22, 2026
2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety
May 21, 2026
2026 ASCO Abstract Highlights: Innovent Biologics’ IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
May 21, 2026
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
May 21, 2026
Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences
May 18, 2026
Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions
May 12, 2026
Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer
May 10, 2026
Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
April 23, 2026
Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
April 23, 2026
Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases
April 9, 2026
1
2
Next Page
→